Discovery of an Orally Bioavailable Small-Molecule Inhibitor for the β-Catenin/B-Cell Lymphoma 9 Protein-Protein

Zhen Wang1, Min Zhang1, Victor Quereda1

  • 1Drug Discovery Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612-9497, United States.

Insights

A new drug, ZW4864, targets the Wnt/β-catenin pathway by disrupting the β-catenin/BCL9 interaction. This approach suppresses cancer cell invasion and shows promise for future drug development.

Area of Science:

  • Molecular Biology
  • Oncology
  • Drug Discovery

Background:

  • Aberrant Wnt/β-catenin signaling drives cancer invasion and metastasis.
  • Targeting β-catenin is a rational strategy, but challenging.
  • Selective disruption of protein-protein interactions (PPIs) is an emerging therapeutic approach.

Purpose of the Study:

  • To identify and characterize a small molecule that selectively inhibits the Wnt/β-catenin pathway.
  • To develop a chemical probe for studying β-catenin biology.
  • To provide a potential therapeutic agent for β-catenin-dependent cancers.

Main Methods:

  • Small molecule screening and characterization.
  • In vitro assays to assess β-catenin signaling inhibition and PPI disruption.
  • In vivo studies using patient-derived xenograft mouse models.
  • Pharmacokinetic profiling.

Main Results:

  • ZW4864 selectively disrupts the β-catenin/BCL9 PPI while sparing the β-catenin/E-cadherin PPI.
  • ZW4864 dose-dependently inhibits Wnt/β-catenin signaling and oncogenic gene expression.
  • ZW4864 abrogates invasiveness of cancer cells and suppresses tumor growth in vivo.
  • ZW4864 exhibits favorable pharmacokinetic properties.

Conclusions:

  • ZW4864 is a potent and selective small-molecule inhibitor of the β-catenin/BCL9 interaction.
  • This compound effectively suppresses Wnt/β-catenin signaling and cancer cell invasiveness.
  • ZW4864 represents a promising drug-like lead for developing novel cancer therapeutics targeting the Wnt pathway.

Related Concept Videos

Catenins01:23

Catenins

Catenins are characterized by multiple binding domains and dynamic structures that allow them to function as linker proteins in cell junction complexes. All catenins, except α-catenin, contain a characteristic protein sequence called the armadillo repeat and are therefore also called armadillo proteins.
Catenins in Cell Junctions
Catenins bind to cell adhesion molecules such as cadherins and link them to different cytoskeletal proteins depending on the type of cell junction. At the...
2.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.1K
Protein-protein Interfaces02:04

Protein-protein Interfaces

Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
14.1K